Company Overview
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.10.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +19.67% |
| 6 Months: | +1.39% |
| 3 Months: | +0.27% |
| 1 Month: | +32.73% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 31.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RCKT Rocket Pharmaceuticals, Inc. R2K | 3.65 | -1.95 | $398.56M | 0.00% | -76.11% | -64.41% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.19M | -2.09M | -3.05M | -3.68M | -5.44M | -10.14M | -8.78M | -10.72M | -2.87M | -3.52M | -6.72M | -6.66M | -14.40M | -14.87M | -15.33M | -26.55M | -18.95M | -18.39M | -19.16M | -19.65M | -24.12M | -23.56M | -27.39M | -59.24M | -39.22M | -34.05M | -49.65M | -42.56M | -54.21M | -58.49M | -62.19M | -68.76M | -65.43M | -67.38M | -73.71M | -69.42M | -64.39M | -71.15M | -52.25M | -48.51M |
| Net Income | -2.85M | -2.39M | -1.46M | -2.39M | -55.96M | -10.07M | -8.68M | -11.13M | -2.68M | -3.52M | -6.72M | -6.66M | -15.34M | -15.77M | -16.09M | -27.32M | -19.45M | -18.68M | -19.28M | -19.86M | -24.66M | -25.04M | -29.08M | -60.92M | -40.18M | -34.52M | -50.12M | -42.98M | -54.40M | -57.76M | -58.34M | -65.70M | -61.90M | -62.05M | -69.65M | -66.72M | -61.33M | -68.92M | -50.33M | -47.59M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.45 | -0.45 | -0.53 | - | -0.65 | -0.55 | -0.79 | -0.67 | -0.83 | -0.87 | -0.73 | -0.82 | -0.75 | -0.66 | -0.74 | -0.71 | -0.56 | -0.62 | -0.45 | -0.42 |
| R&D Expense | 1.86M | 1.24M | 1.07M | 1.95M | 3.61M | 7.62M | 6.46M | 8.41M | 2.29M | 2.82M | 4.89M | - | 5.74M | 10.77M | 13.06M | - | 15.14M | 13.99M | 14.83M | - | 16.96M | 16.73M | 21.66M | - | 28.31M | 24.53M | 39.62M | 30.79M | 41.36M | 43.38M | 46.37M | 51.38M | 46.84M | 45.23M | 46.34M | 42.31M | 35.94M | 42.66M | 34.07M | 31.45M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | 223.84M | 259.66M | 273.20M | 228.52M |
| Operating Income | -7.70M | -20.40M | -7.57M | -19.77M | -71.16M | -76.15M | -134.30M | - | -223.84M | -259.66M | -273.20M | -228.52M |
| EBITDA | - | - | - | - | - | - | - | - | -213.69M | -236.62M | -247.49M | -210.21M |
| Interest Expense | - | - | - | - | - | - | - | - | 1.91M | 1.88M | 1.89M | 1.89M |
| Pretax Income | - | - | - | - | - | - | - | - | -221.86M | -245.59M | -258.75M | -223.12M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -9.53M | -67.98M | -7.57M | -19.58M | -74.52M | -77.27M | -139.70M | - | -221.86M | -245.59M | -258.75M | -223.12M |
| Diluted EPS | - | - | - | - | - | -1.58 | -2.52 | - | -3.26 | -2.92 | -2.73 | -2.01 |
| R&D Expense | 5.59M | 12.55M | 5.99M | 14.92M | 53.27M | 57.91M | 105.44M | 125.48M | 165.57M | 186.34M | 171.24M | 142.01M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 5.52M | 113.32M | 129.65M | 20.15M | 251.31M | 372.12M | 590.82M | 497.02M | 551.81M | 566.34M | 527.70M | 330.45M |
| Total Equity | -38.90M | -51.56M | 15.54M | 8.37M | 15.52M | 194.04M | 307.30M | 503.52M | 454.72M | 489.69M | 492.57M | 463.23M | 277.22M |
| Cash & Equivalents | 12.79M | 3.62M | 80.04M | 29.80M | 18.14M | 111.36M | 185.38M | 297.10M | 232.69M | 140.52M | 55.90M | 163.63M | 77.56M |
| Total Liabilities | - | 10.28M | 4.51M | 56.48M | 4.63M | 57.28M | 64.82M | 87.31M | 42.30M | 62.12M | 73.77M | 64.47M | 53.23M |
| Current Liabilities | - | 7.22M | 4.14M | 7.04M | 4.52M | 15.37M | 18.31M | 32.62M | 22.17M | 39.17M | 48.51M | 40.68M | 30.21M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.50M | -15.96M | -53.79M | -64.66M | -74.64M | -121.16M | -178.14M | -194.92M | -209.72M | -190.01M |
| Investing Cash Flow | -335.00K | -760.00K | -5.27M | -39.01M | -96.59M | 18.85M | -69.33M | -98.07M | 131.71M | 103.77M |
| Financing Cash Flow | 16.00K | 25.41M | 153.50M | 177.79M | 282.99M | 37.68M | 155.29M | 208.40M | 185.74M | 148.00K |
| Capital Expenditure | -335.00K | -760.00K | -1.45M | -23.27M | -20.61M | -7.62M | -8.36M | -16.44M | -5.86M | -440.00K |
| Free Cash Flow | -5.84M | -16.72M | -55.24M | -87.93M | -95.25M | -128.78M | -186.50M | -211.35M | -215.59M | -190.45M |
| Share Buybacks | 0 | 0 | 0 | 0 | 72.00K | 0 | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 18.5% | -437.5% | -90.5% | -126.2% | -38.4% | -25.1% | -27.7% | - | -45.3% | -49.9% | -55.9% | -80.5% |
| ROCE % | 452.6% | -18.7% | -6.2% | -126.5% | -30.2% | -21.5% | -24.1% | - | -43.7% | -50.1% | -56.1% | -76.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RTW Investments LP | 16.20% | 17.69M | $64.83M |
| 2 | Blackrock Inc. | 7.18% | 7.83M | $28.71M |
| 3 | Citigroup Inc. | 4.68% | 5.11M | $18.72M |
| 4 | Vanguard Portfolio Management LLC | 4.30% | 4.69M | $17.19M |
| 5 | State Street Corporation | 4.11% | 4.49M | $16.44M |
| 6 | Vanguard Capital Management LLC | 3.46% | 3.78M | $13.84M |
| 7 | Maverick Capital Ltd. | 3.27% | 3.57M | $13.07M |
| 8 | Newtyn Management, Llc | 2.90% | 3.17M | $11.60M |
| 9 | Nuveen, LLC | 2.87% | 3.13M | $11.47M |
| 10 | Millennium Management Llc | 2.86% | 3.12M | $11.43M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RCKT
RCKT Stock Jumps Over 10% Premarket: FDA Approves Its First Gene Therapy For Rare Childhood Immune Disease - Stocktwits
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQSkVhUUZPZHRPR3M1SkoyTXBBSlZTaFB2S2hTQzF3VHVudnFLYnVibkVxOWJrWUhoSC1ocFNDbUswOExoV09VSzh4ZjYyMkZZeC16b1I2SlBsWFRIMXZ5c0lOMDQtSWU3TWhNSE5NQ2tUODVTSWVkb183V0wwdEgwdmItaE50NXBlcEw3Nz…
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQbUkyekpmQzJPTUY2c0x0djJ1c1lzZkJCWmk4ZzRJZ0hVSmNCQjlTMmtqTDNOQmpUN2JDN29FZ0U3bDRuQ3RDSzZzQlZvOXYzR0RKLVh6MUFNUEczWWdxTDkwV3Y3aG9RMkhSVC1uelV0eWZWYzBwZDdrb1RhaGloY0JoWVBXbU9iWHRCNH…
$RCKT stock is down 8% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOWnFsMWhJSkFKT2UzRGsyTFNBTTBqTk5pejFqZjdqX1B5YmE4Y2RMR3pxMW15bUlOX0xNOVVJRmpzYWFOT1UwV2NDaENDeE1UV25JcWduWFZSX0hrTzhqME9JZ01rVV94SURfcHpOZUhCYmFSaUtzdW1SSFBCVkdVM0VteTVXc2tOYTcwY3…
If You Invested $1,000 in Rocket Pharmaceu (RCKT) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5udUFjcGNiQVZGSHloQnJBZTZaRUR2TVhmcVU4V1ZVY0thZ1lSSDUxOWNmbG4wSy16TnBXTlo1LTJUU045ZTFsRDdlWnd5Zl9WRnl0TUNvQjVjSWY3M2p1WWczT09sVUZoazA0RFF3?oc=5" target="_blank">If You Invested $1,…
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOTXdfNXpUay1sMlU2LW9TeEcwMUdVRkljX3V3dGRCWm1MemRVeTBwTEQ4M3N0M1VMNWl4VVJQMDV6cDgtdGxkbjJwWEtnODJ5Q3VIVFZJQ1BZbUNaOUhtRHE4U3FIZkE3c08tWmV1dE1GU0h0ei0wU0ZSdnBSWURIOFB6RWxPaWw0M1ZXTz…
RCKT Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9nYTNCTWtsMmE3X0U4ZlYxVWc2NXRWM2tkNHg4V0pCNjFRVm12ajg3MFlVLUZoZm82R0VjWGt4MGl6UjZUd01Xamgya2Q2UFFpQ21UYUpaa25XcVN1QzJyazNfcG5tbksxVm1XMUhfWmlSdjFUWFkyZ0pR?oc=5" target="_blank">RCK…
RCKT — Frequently Asked Questions
What is the current share price of Rocket Pharmaceuticals, Inc. (RCKT)?
As of 2026-07-15 16:51 PDT, Rocket Pharmaceuticals, Inc. (RCKT) trades at $3.65 on NasdaqGM. Its 52-week range is $2.60 to $5.30.
What is the market capitalisation of RCKT?
Rocket Pharmaceuticals, Inc. (RCKT) has a market capitalisation of $398.56M on NasdaqGM.
What is the P/E ratio of RCKT?
RCKT trades at a trailing price-to-earnings (P/E) ratio of -1.95. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 1.68.
What is the return on equity (ROE) of RCKT?
RCKT has a return on equity (ROE) of -64.41%. Its return on capital employed (ROCE) is -76.11%.
Is RCKT a good stock to buy?
This page provides a data-driven analysis of Rocket Pharmaceuticals, Inc. (RCKT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.